Adherence to antiretroviral therapy and acceptability of planned treatment interruptions in HIV-infected children by Harrison, L. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/117467
 
 
 
Please be advised that this information was generated on 2017-12-05 and may be subject to
change.
ORIGINAL PAPER
Adherence to Antiretroviral Therapy and Acceptability
of Planned Treatment Interruptions in HIV-Infected Children
Linda Harrison • Jintanat Ananworanich • Djamel Hamadache • Alexandra Compagnucci •
Martina Penazzato • Torsak Bunupuradah • Antonio Mazza • Jose Tomas Ramos •
Jacquie Flynn • Osvalda Rampon • Maria Jose Mellado Pena • Daniel Floret • Magdalena Marczynska •
Ana Puga • Silvia Forcat • Yoann Riault • Marc Lallemant • Hannah Castro • Diana M. Gibb •
Carlo Giaquinto • On Behalf of the Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial Team
Published online: 15 May 2012
 The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract There have been no paediatric randomised tri-
als describing the effect of planned treatment interruptions
(PTIs) of antiretroviral therapy (ART) on adherence, or
evaluating acceptability of such a strategy. In PENTA 11,
HIV-infected children were randomised to CD4-guided
PTIs (n = 53) or continuous therapy (CT, n = 56). Carers,
and children if appropriate, completed questionnaires on
adherence to ART and acceptability of PTIs. There was no
difference in reported adherence on ART between CT and
PTI groups; non-adherence (reporting missed doses over
the last 3 days or marking\100 % adherence since the last
clinical visit on a visual analogue scale) was 18 % (20/111)
and 14 % (12/83) on carer questionnaires in the CT and
PTI groups respectively (odds ratios, OR (95 % CI) = 1.04
(0.20, 5.41), v2 (1) = 0.003, p = 0.96). Carers in Europe/
USA reported non-adherence more often (31/121, 26 %)
than in Thailand (1/73, 1 %; OR (95 % CI) = 54.65 (3.68,
810.55), v2 (1) = 8.45, p = 0.004). The majority of fam-
ilies indicated they were happy to have further PTIs (carer:
23/36, 64 %; children: 8/13, 62 %), however many repor-
ted more clinic visits during PTI were a problem (carer:
15/36, 42 %; children: 6/12, 50 %).
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del tratamiento (IPT) antirretroviral en el seguimiento del
tratamiento o en la aceptabilidad de dicha estrategia. En
PENTA11, nin˜os infectados con HIV fueron randomizados
o bien en IPT guiadas por sus CD4 (n = 53) o bien en
terapia continua (TC, n = 56). Tanto los cuidadores como
los nin˜os, cuando era apropiado, completaron cuestionarios
de seguimiento de la terapia antirretroviral y de
aceptabilidad de las interrupciones. No se encontro´
diferencia en cuanto al seguimiento del tratamiento entre
los dos grupos. No seguimiento (dosis perdidas durante los
u´ltimos 3 dı´as o\100 % desde la ultima visita a la clı´nica
en una escala visual analo´gica) fue del 18 % (20/111) y del
14 % (12/183) en los cuestionarios de los cuidadores en TC
y en IPT respectivamente (odds ratios, OR (95 % CI) =
1.04 (0.20, 5.41), v2 (1) = 0.003, p = 0.96). Los cuidadores
en Europa/USA informaron de un no seguimiento del
tratamiento ma´s a menudo (31/121, 26 %) que en Tailandia
(1/73, 1%; OR (95 % CI) = 54.65 (3.68, 810.55), v2 (1) =
8.45, p = 0.004). La mayorı´a de las familias indicaron que
les gustarı´a realizar ma´s ITP (cuidador: 23/36, 64 %; nin˜os:
8/13, 62 %), sin embargo muchos indicaron que el mayor
numero de visitas a la clı´nica durante la IPT era un
problema (cuidador: 15/35, 43 %; nin˜os: 6/12, 50 %).
Keywords Adherence  Acceptability 
Planned treatment interruptions  HIV  Children
Introduction
AIDS related mortality and morbidity has declined sub-
stantially in HIV-infected children since the introduction of
combination antiretroviral therapy (ART) [1, 2]. However,
complete HIV suppression requires a high level of adher-
ence to ART to be sustained over a lifetime [3, 4]. In
children, the life-long exposure to treatment also raises
concerns regarding potential long-term toxicity such as
lipodystrophy, osteopenia, and mitochondrial dysfunction
[5, 6]. Additionally, treatment sequencing, given the
greater potential for inadequate dosing and the absence of
appropriate licensed drug formulations, is often challeng-
ing [7]. Therefore, planned treatment interruptions (PTIs)
may be welcomed by children and their families, but may
also have a negative impact on adherence once ART is re-
started.
Trials evaluating treatment interruptions in adults have
reported higher rates of AIDS events/death and serious
non-AIDS events in those stopping ART [8–12], and the
SMART trial reported that CD4-guided episodic use of
ART resulted in inferior quality of life (QOL) [13].
PENTA 11 was a pilot study evaluating CD4-guided PTIs
in HIV-infected children and the key finding of the trial
was that no serious clinical outcomes were reported in
children undergoing PTIs [14]. Nevertheless, there was a
significant excess of minor clinical events in the PTI group
after stopping ART, compared to children on continuous
therapy (CT), which may have been problematic for chil-
dren and families.
There have been no paediatric studies describing the
effect of PTIs on adherence within a randomised trial, or
evaluating acceptability of such a strategy. In the PENTA
11 trial, adherence to ART and acceptability of PTIs was
measured routinely, and this paper presents findings from
analyses of these data.
Methods
Trial Design
PENTA 11 was an open, multicentre, randomised, phase II,
trial (ISRCTN36694210) in HIV-infected children aged
2–15 years, on any ART regimen containing C3 drugs
which had been taken for C24 weeks. Eligibility to par-
ticipate also required that the two most recent plasma
HIV-1 RNA measurements were \50 copies/ml and the
two most recent CD4 % measurements were C30 % (ages
2–6 years) or C25 % and CD4 count C500 cells/mm3
(7–15 years) [14]. Children were randomised in a 1:1 ratio
to either continue ART (CT) or stop ART and then follow a
strategy of CD4-guided PTI (ART was restarted if con-
firmed CD4 % was less than 20 % or more than 48 weeks
had been spent off ART; ART could be stopped again after
24 weeks on ART and confirmed CD4 % was C30 % (ages
2–6 years) or C25 % and CD4 count C500 cells/mm3
(7–15 years); see Fig. 1 in the main trial publication for
further details on the design of the trial [14]), for at least
72 weeks. The protocol was approved by the ethics com-
mittee for each participating centre (listed in Acknowl-
edgments). All parents/guardians gave written consent, and
children gave written assent, according to their age and
knowledge of HIV status.
Adherence Questionnaires
Carers, and children if appropriate, were asked to complete
adherence questionnaires, adapted from previous PENTA
studies [15, 16], at baseline, weeks 24, 48 and 72 in the CT
group, and at baseline, then at 4, 12, 24 and 48 weeks after
each ART re-start in the PTI group. Questionnaires were
completed at the time of scheduled clinic visits; with the
help of the nurse or doctor if required.
Adherence was assessed by a question used in previous
PENTA studies to measure adherence [15, 16]; ‘‘Can you
say how many times your child has/you have missed a dose
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of antiretroviral medicines over the last 3 days?’’ Addi-
tionally, carers, and children if appropriate, were asked to
mark adherence to ART since the last clinical visit on a
visual analogue scale (VAS) consisting of a line ranging
from 0 to 100 % [17]. Clear instructions were given as
follows; that 0 % meant no medicines had been taken since
the last clinic visit, 50 % meant about half the medicines
were taken, and 100 % meant that no doses of any of the
medicines had been missed. Both questions were used to
assess adherence, the first which had been used before in
the study population, and the second to capture adherence
between visits.
Acceptability Questionnaires
Carers, and children if appropriate, randomised to PTI were
asked to complete an acceptability questionnaire, adapted
from a previous PENTA study [16], at baseline (protocol
amendment) and again at the end of the study.
Participants were asked to choose from five options
about how they thought stopping medicines as part of a
planned treatment interruption would affect them and the
rest of their family. In addition, at baseline, they were
asked if they had any concerns about the possible disad-
vantages of a PTI, and at the end of the study if they were
happy to undergo further PTIs. Other structured questions
included asking about problems while on PTIs and with re-
starting medicines following a PTI, as well as asking if
there was any difference giving or taking medicines before
or after a PTI.
Statistical Analysis
Non-adherence was defined as either reporting one or more
missed doses over the last 3 days and/or marking \100 %
on the VAS. Due to the different proportion of question-
naires completed in Europe/USA and Thailand, analyses
were performed by region as well as by randomised group.
As the design of the study meant that the PTI group
restarted ART at different times, adherence data from
questionnaires from all time points were combined per
group and analysed together (including data from ques-
tionnaires completed after each ART restart in the PTI
group). For comparisons over time, data from each time
point were compared (data after the first restart only in the
PTI group). Carer or child questionnaires not completed at
all at particular time points were omitted from all analyses;
individual questions not answered on carer/child ques-
tionnaires which had been partly completed were omitted
from the analysis of that question. Comparisons of pro-
portions were analysed using Chi-squared (v2) tests and
differences in medians using the Wilcoxon rank-sum test.
Multilevel univariate logistic regression was used to ana-
lyse the results of multiple questionnaires per person
completed during follow-up; fixed-effects odds ratios (OR)
and confidence intervals (CI) are reported.
Results
PENTA 11 randomised 110 children from three continents
between November 2004 and December 2006: Europe (83
children), USA (4), Thailand (23). One child (randomised
in error) was excluded, leaving 109 children (53 CT, 56
PTI) included in the analysis. At baseline the median age
was 9 (range 2–16) years, and median CD4 % was 37 %
(interquartile range (IQR): 33, 41) (see Table 1 in the main
trial publication for further details of the baseline charac-
teristics [14]). In the PTI group, 19 (34 %) children
reached the CD4-guided ART restart criteria between 6 and
42 weeks after stopping ART, 32 (57 %) restarted ART
because they had been off ART for 48 weeks, four
restarted for other reasons and one child did not restart
ART for social reasons. Sixteen children had a second PTI,
and no child had a third PTI. No child died or had a new
CDC C diagnosis, and 1 child (2 %) in the CT group versus
4 (7 %) in the PTI group (difference 5, 95 % CI -2 to
?13 %; adjusted OR (95 % CI) = 4.09 (0.42, 39.78), v2
(1) = 1.47, p = 0.23) reached a CD4 outcome [14].
However, 50 clinical events, mainly grade 2, were reported
in 29 (52 %) PTI children compared with 26 in 15 (28 %)
CT children (rate ratio (95 % CI) = 2.35 (1.27–4.39),
z = 2.87, p = 0.004) (see Table 2 in the main trial publi-
cation for full details of the clinical events reported [14]).
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Fig. 1 Non-adherence during follow-up by randomised group and
region. Non-adherence was defined as reporting one or more missed
doses over the last 3 days and/or marking \100 % adherence since
the last clinical visit on the VAS. All child questionnaires were
completed in Europe/USA. CT continuous therapy, PTI planned
treatment interruption
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At baseline, carer reported non-adherence was similar
across randomised groups, but carers in Europe/USA
reported non-adherence more often than in Thailand
(Table 1; Europe/USA 6/51, 12 %; Thailand 0/23, 0%; v2
(1) = 2.94, p = 0.09). Carer questionnaires in Europe/
USA were mainly completed by the mother/father (mother:
54/86, 63 %; father: 10/86, 12 %), while in Thailand it was
predominantly another carer (17/23, 74%; v2 (2) = 35.97,
p \ 0.001). Additionally children enrolled in Europe/USA
had been exposed to ART for longer than those from
Thailand (median [IQR]: Europe/USA 7.0 years [4.7, 9.2],
Thailand 2.9 years [2.0, 3.9]; z = -5.49, p \ 0.001), but
fewer were reported to have knowledge of their infection
status (Europe/USA 31/67, 46 %; Thailand 15/23, 65 %).
Children in Europe/USA reported similar baseline non-
adherence across randomised groups (Table 1); children in
Thailand did not complete questionnaires.
Adherence Questionnaires During Follow-Up
At least one adherence questionnaire was completed during
follow-up by a carer for 49/53 (92 %) children in the CT
and 46/56 (82 %) in the PTI group (v2 (1) = 2.59, p =
0.11) (Table 2). The proportion of returned carer ques-
tionnaires was higher in Thailand (73/75, 97 %) compared
to Europe/USA (134/289, 46 %;OR (95 % CI) = 0.0072
Table 1 Characteristics by
randomised group and region
ART antiretroviral therapy, CT
continuous therapy, PTI planned
treatment interruption, ABC
abacavir, 3TC lamivudine, NVP
nevirapine, EFZ efavirenz, d4T
stavudine, AZT zidovudine, IQR
inter-quartile range, NRTI
nucelos(t)ide reverse
transcriptase inhibitor, NNRTI
non-nucleoside reverse
transcriptase inhibitor, PI
protease inhibitor
a Nine children (five Europe/
USA CT and four Europe/USA
PTI) were South American, four
(two Europe/USA CT and two
Europe/USA PTI) were mixed
black/white and one (Europe/
USA PTI) was American Indian
b Non-adherence was defined as
either reporting one or more
missed doses over the last three
days or marking \100 %
adherence since the last clinical
visit on the VAS
c On or before the last
adherence questionnaire
d Only counted as not known if
child is [10 years and in
Europe/USA. In Thailand
questionnaires were only
completed by carers
Europe/USA CT Europe/USA PTI Thailand CT Thailand PTI
Number of children 41 (1 in USA) 45 (3 in USA) 12 11
Age at baseline (years)
Median (IQR) 10.1 (7.1–12.0) 9.3 (6.8–12.0) 8.0 (5.8–12.9) 8.2 (6.7–11.4)
10 to \16 (%) 21 (54) 19 (42) 5 (42) 3 (27)
Gender (%)
Male 17 (42) 23 (51) 5 (41) 4 (36)
Ethnic origin (%)
White 17 (42) 21 (47) 0 (0) 0 (0)
Black 17 (42) 17 (38) 0 (0) 0 (0)
Asian 0 (0) 0 (0) 12 (100) 11 (100)
Othera 7 (17) 7 (16) 0 (0) 0 (0)
CD4 %
Median (IQR) 37 (35–41) 37 (33–43) 35 (32–38) 34 (32–41)
Carer reported non-adherenceb at baseline (%)
Yes 1 (2) 5 (11) 0 (0) 0 (0)
No 25 (61) 20 (44) 12 (100) 11 (100)
Not known 15 (37) 20 (44) 0 (0) 0 (0)
Relative who completed most carer questionnairesc (%)
Mother 28 (68) 26 (58) 3 (25) 1 (9)
Father 4 (10) 6 (13) 1 (8) 1 (9)
Other carer 1 (2) 7 (16) 8 (67) 9 (82)
Not known 8 (20) 6 (13) 0 (0) 0 (0)
Cumulative ART exposure prior to baseline (years)
All median (IQR) 7.5 (5.3–9.4) 6.1 (4.6–8.6) 2.9 (1.8–3.9) 2.8 (2.5–3.7)
NRTIs median (IQR) 7.5 (5.3–9.2) 6.1 (4.3–8.3) 2.9 (1.8–3.9) 2.8 (2.5–3.1)
NNRTIs median (IQR) 1.4 (0.0–4.3) 3.2 (0.0–5.1) 2.9 (1.8–3.9) 2.8 (2.5–3.1)
PIs median (IQR) 4.3 (0.0–5.7) 2.7 (0.0–5.3) 0.0 0.0
Childd reported non-adherenceb at baseline (%)
Yes 2 (10) 0 (0)
No 10 (47) 6 (32)
Not known 9 (43) 13 (68)
Knowledge of HIV infection statusc (%)
Yes 16 (39) 15 (33) 8 (67) 7 (64)
No 17 (41) 19 (42) 4 (33) 4 (36)
Not known 8 (20) 11 (24) 0 (0) 0 (0)
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(0.00097, 0.054), v2 (1) = 23.12, p \ 0.001). The num-
ber of questionnaires completed did not differ over
time in either randomised group for carers or children
(Table 2).
The question on missed doses over the last 3 days was
answered on 182/207 (88 %) carer questionnaires and the
VAS was marked on 160/207 (77 %). 2/194 (1 %) reported
both missed doses and marked at \100 % on the VAS, 5
(3 %) reported missed doses but did not mark the VAS, and
25 (13 %) marked at \100 % on the VAS (of which 19
reported no missed doses in the last 3 days and 6 did not
answer the question). This led to an overall non-adherence
rate of 32/194 (16 %) during follow-up.
Figure 1 shows the reported non-adherence by ran-
domised group and region. There was no difference in carer
reported non-adherence between CT and PTI groups (18
vs. 14 % respectively; OR (95 % CI) = 1.04 (0.20, 5.41),
v2 (1) = 0.003, p = 0.96) and it did not differ over time on
CT (week 24: 14 % (5/37), week 48: 20 % (7/35), week 72:
21 % (8/39); v2 (2) = 1.56, p = 0.46) or after first re-start
in PTI group (week 4: 21 % (4/19), week 12: 11 % (2/19),
week 24: 21 % (5/24), week 48: 0 % (0/14); v2 (2) = 1.00,
p = 0.61, week 48 omitted from model). Carers reported
non-adherence more often in Europe/USA than in Thailand
(26 vs. 1 % respectively; OR (95 % CI) = 54.65 (3.68,
810.55), v2 (1) = 8.45, p = 0.004).
Table 2 Questionnaires completed during follow-up by randomised group and region
Total number completed Carer overall (%) Carer Europe/USA (%) Carer Thailand (%) Childrena Europe/USA (%)
Adherence CTb
Overall during follow-up 116/159 (73) 80/123 (65) 36/36 (100) 31/69 (45)
At week 24 38/53 (72) 26/41 (63) 12/12 (100) 7/22 (32)
At week 48 36/53 (68) 24/41 (59) 12/12 (100) 12/23 (52)
At week 72 42/53 (79) 30/41 (73) 12/12 (100) 12/24 (50)
Adherence PTIc
Overall during follow-up 91/205 (44) 54/166 (33) 37/39 (95) 35/76 (46)
After first re-startd 84/188 (45) 50/152 (33) 34/36 (94) 27/62 (44)
At week 4 20/53 (38) 12/44 (27) 8/9 (89) 7/19 (37)
At week 12 22/53 (42) 14/44 (32) 8/9 (89) 7/19 (37)
At week 24 26/50 (52) 17/41 (42) 9/9 (100) 9/17 (53)
At week 48 16/32 (50) 7/23 (30) 9/9 (100) 4/7 (57)
After second re-start 7/17 (41) 4/14 (29) 3/3 (100) 8/14 (57)
At week 4 3/7 (43) 2/6 (33) 1/1 (100) 2/5 (40)
At week 12 2/6 (33) 1/5 (20) 1/1 (100) 2/5 (40)
At week 24 2/4 (50) 1/3 (33) 1/1 (100) 3/3 (100)
At week 48 1/1 (100)
Acceptability PTI
Baselinee 18/35 (51) 15/26 (58) 3/9 (33) 9/15 (60)
End of the study 37/56 (66) 27/45 (60) 10/11 (91) 14/23 (61)
Children with at least one
Adherence CT 49/53 (92) 37/41 (90) 12/12 (100) 21/26 (81)
Adherence PTI 46/56 (82) 35/45 (78) 11/11 (10) 22/26 (85)
Acceptability PTI 43/56 (77) 33/45 (73) 10/11 (91) 19/25 (76)
CT continuous therapy, PTI planned treatment interruption
a Only counted as missing if child is [10 years
b Carer: OR (week 48 vs. 24, 95 % CI) = 0.78 (0.29, 2.08), OR (week 72 vs. 24, 95 % CI) = 1.75 (0.61, 5.02), v2 (2) = 2.35, p = 0.31
Children: OR (week 48 vs. 24, 95 % CI) = 3.92 (0.74, 20.82), OR (week 72 vs. 24, 95 % CI) = 3.31 (0.64, 17.14), v2 (2) = 2.93, p = 0.23
c Two children restarted ART at the end of the study, one child did not restart ART
d Carer: OR (week 12 vs. 4, 95 % CI) = 1.42 (0.44, 4.57), OR (week 24 vs. 4, 95 % CI) = 3.43 (0.99, 11.80), OR (week 48 vs. 4, 95 %
CI) = 1.65 (0.42, 6.46), v2 (3) = 3.99, p = 0.26
Children: OR (week 12 vs. 4, 95 % CI) = 1.00 (0.16, 6.33), OR (week 24 vs. 4, 95 % CI) = 3.51 (0.50, 24.59), OR (week 48 vs. 4, 95 %
CI) = 3.54 (0.27, 47.05), v2 (3) = 2.44, p = 0.49
e Only counted as missing if after the protocol amendment: October 2005
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Children from Europe/USA who completed question-
naires were of a median (IQR) age of 11 (10–14) years.
Non-adherence was reported by these children on 35 %
(22/63) of questionnaires but did not differ by randomised
groups (Fig. 1, CT 30 %; PTI 39 %; OR (95 % CI) = 3.10
(0.25, 37.79), v2 (1) = 0.79, p = 0.38) or over time (CT v2
(2) = 1.09, p = 0.58; PTI after first re-start, v2 (3) = 4.20,
p = 0.24). On the 36 occasions when both the child and
their carer completed separate questionnaires, non-adher-
ence was reported by both on eight occasions and only the
child on 2.
Acceptability Questionnaires
Small numbers of acceptability questionnaires were com-
pleted at baseline as these were only included in a protocol
amendment after the trial had started (October 2005).
Overall questionnaire return rates among carers who were
offered questionnaires were 13/20 (65 %) in Thailand and
42/71 (59 %) in Europe/USA (OR (95 % CI = 0.79 (0.23,
2.73), v2 (1) = 0.14, p = 0.71) (Table 2).
At baseline, 94 % (17/18) of carers and 89 % (8/9) of
children thought PTIs would make life easier, decreasing to
65 % (24/37, v2 (1) = 2.02, p = 0.16) of carers and 79 %
(11/14, v2 (1) = 0.37, p = 0.54) of children by the end of
the study; Europe/USA carers reported PTIs more favour-
ably (overall: Europe/USA easier 34/42, 81 %; Thailand
7/13, 54 %; v2 (1) = 3.84, p = 0.05) (Fig. 2). At baseline
only 5/18 (28 %) of carers (Europe/USA 4/15, 27 %;
Thailand 1/3, 33 %) and 2/8 (25 %) children had concerns
about the possible disadvantages of PTI, and at the end of
the study most carers (23/36, 64 %) and children (8/13,
62 %) were happy to have further PTIs (Fig. 3). However,
again there were differences by region; in Europe/USA
21/26 (81 %) carers said they were happy, but in Thailand
opinion was split (yes 2/10, 20 %; no 3/10, 30 %; not sure
5/10, 50 %; v2 (1) = 11.56, p = 0.001).
Approximately half of the carers (Europe/USA 12/26,
46 %; Thailand 3/10, 30 %) and children (6/12, 50 %) at
the end-of study had found more clinic visits during PTI a
problem. Two thirds of children said they did not want to
start medicines again following a PTI (7/11, 64 %), but a
lower proportion of carers reported this being a problem
(Europe/USA 7/20, 35 %, Thailand 2/10, 20 %). When
asked if there was any difference giving/taking medicines
before and following a PTI, most carers (Europe/USA
16/25, 64 %; Thailand 8/10, 80 %) and children (9/13,
69 %) said there was no difference.
Few carers and children said feeling ill (carer: Europe/
USA 3/22, 14 %; Thailand 2/10, 20 %; children: 1/12,
8 %), developing minor signs/symptoms (carer: Europe/
USA 6/22, 27 %; Thailand 0/10, 0 %; children: 0/12, 0 %),
or feeling anxious (carer: Europe/USA 4/17, 24 %; Thai-
land 1/10, 10 %; children: 1/11, 9 %) during a PTI were
problems. Of the 29 children in the PTI group with reported
clinical events, few at the end of the study reported feeling
ill (1/16), developing minor signs/symptoms (3/15) or
feeling anxious (4/15) were problems.
Discussion
Overall, reported adherence to ART was similar in the CT
and PTI groups, and participants reported that PTIs gen-
erally made life easier. The majority of children and carers
were happy to have further PTIs, and only a few experi-
enced problems with treatment interruptions.
PTIs did not seem to impact negatively on adherence,
and the reported adherence rate remained stable over time.
These observations are similar to those reported in the
Trivacan ANRS 1269 trial in adults [9], where non-
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stopping medicines as part of a PTI make things for you?’’, by
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missed dose in the last 4 days, were 11.1 % in the CT
group and 11.3 % in the interruption group. Reported
adherence was also comparable to previous non-interrup-
tion studies in children, which used similar questionnaires.
For example, PACTG 219C [18] reported ‘‘missed doses
over the 3 days before the study visit’’ for 324/2088 (16 %)
subjects and PENTA 5 [15] reported ‘‘forgot one or more
doses in the last 7 days’’ on 69/265 (26 %) questionnaires.
A recent literature review on paediatric adherence to ART
[19] revealed a comparable overall adherence rate of 73 %
when adherence was assessed by caregiver report.
Better adherence was reported in Thailand than Europe/
USA. This is in line with the recent literature review [19],
where adherence was better in low/middle income com-
pared to high-income countries. Correspondingly, Thai
carers found PTIs less acceptable, and it therefore appears
carers in Thailand preferred to give ART medication rou-
tinely. There could be a number of reasons for this obser-
vation. Firstly, Thai carers may have had concerns about
their children falling ill when ART was stopped; ART only
became widely available in Thailand in the last few years
and before ART was introduced, about 500,000 adults and
12,000 children died of AIDS [20]. Secondly, most ques-
tionnaires in Thailand were completed by a carer other than
the child’s parents. It is possible that the non-biological
parents in Thailand, usually grandparents or relatives, have
witnessed one or more family members dying of AIDS;
therefore, they are more concerned about the children not
being on continuous ART. Lastly, at baseline, all children
from Thailand had only been exposed to two ART classes
and, on average, had taken ART for a much shorter period
of time (median \3 years) than children in Europe/USA.
Therefore the desire to stop medication may have been less
than is Europe/USA, where children had already taken
ART for a median of 7 years.
An excess of minor clinical events; mainly haemato-
logical/lymphatic system disorders, dermatological
(rashes) and CNS/psychiatric (most commonly headaches),
were observed in PTI group of PENTA 11 [14]. However,
these events did not appear to impact on acceptability of
PTIs. Instead, carers and children reported that practical
issues, such as more clinic visits and re-starting medica-
tion, were more problematic than illness. Though mainly
descriptive, comments on acceptability questionnaires were
of interest. They were mainly positive, and included ‘‘She
will have a break, she can enjoy staying over with friends
and family who don’t know her diagnosis’’, ‘‘no need to
wake up early’’, ‘‘I have been very well without treatment’’,
and ‘‘The child had normal life’’. However, a number of
children commented on practical problems; ‘‘I have now
restarted the medication and I am finding this more difficult
because of short term side effects’’, and ‘‘I had to go to the
clinic every 2 weeks’’.
Although using a different tool in smaller numbers, our
results differ from the SMART [13] and DART [21] trials
in adults. In SMART a total of 1225 patients had QOL
assessments over a mean follow-up time of 2.4 years, and
whenever QOL outcomes differed, the results were inferior
among patients in the CD4-guided episodic therapy group
compared with the CT group; excluding participants with
disease progression had minimal effect on QOL compari-
sons [13]. Participants in the DART trial completed
acceptability questionnaires at termination of structured
treatment interruption (STI) (n = 408): 36 % reported
STIs made things ‘‘a little/lot harder’’, 31 % ‘‘no different’’
and 32 % ‘‘a little/lot easier’’ [21]. Similarly, higher pro-
portions of participants in the STI group within DART
reported feeling ill (38 %) or anxious (42 %) was a prob-
lem during STI, than in PENTA 11. However comparable
proportions of DART participants said they were willing to
interrupt ART again (62 %). Of note, CD4 counts at
interruption in both SMART and DART trials were lower
than in PENTA 11; however, although DART patients had
late stage HIV disease, it is also true that 26 % of children
in PENTA 11 had experienced an AIDS event prior to
entry.
Two smaller studies in adults observed no difference in
QOL for patients experiencing STIs. Firstly, the STAC-
CATO trial (n = 379) [22] observed no difference in QOL
or mental health between the CT and CD4-guided inter-
ruption arms. Secondly, the AIDS Clinical Trials Group
5170 observational study of 167 asymptomatic HIV-
infected patients who wished to discontinue ART found
QOL did not change during a prolonged treatment inter-
ruption [23].
There are several limitations of this study; firstly, the
low questionnaire return rate, particularly in the PTI group
within Europe/USA. Although reasons for not completing a
questionnaire were not formally collected, comments from
staff at the participating European sites were that they were
reluctant to give patients the questionnaires so regularly, as
families already had lengthy clinic appointments, espe-
cially in the PTI group. Secondly, the small sample size of
children from Thailand means the role of bias when com-
paring Europe/USA and Thailand cannot be ruled out.
Thirdly, the assessment of adherence was through self-
reported measures and therefore the results presented are a
subjective measure of adherence. Also, the VAS had not
been used to assess adherence in this population previ-
ously. Lastly, combining adherence data from question-
naires from all time points per group meant that
comparisons between groups at specific time points were
not made.
PENTA 11 was a pilot study in children, and the strat-
egy of treatment interruptions needs further evaluation
within a larger trial to clarify whether PTIs have a future
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role in paediatric HIV management. Two large African
paediatric treatment interruption trials will report shortly
(BANA II [24] and CHER [25]), and will further assess the
impact of PTIs on the QOL in children. However, in the
subset of children who answered questionnaires, treatment
interruptions do not appear to have a negative impact on
reported adherence, although adherence was lower in
Europe/USA than Thailand. The acceptability of PTIs was
reasonable in this small sample, with the majority of
families indicating they were happy to have further PTIs.
Increased clinic visits and re-starting ART after PTI
appeared to be the main issues with treatment interruption.
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